Aptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report released on Sunday morning. The firm issued a hold rating on the biotechnology company’s stock.

A number of other research firms also recently commented on APTO. Canaccord Genuity Group dropped their target price on shares of Aptose Biosciences from $15.00 to $6.00 and set a buy rating on the stock in a research report on Thursday, May 16th. HC Wainwright reaffirmed a buy rating and issued a $7.00 target price on shares of Aptose Biosciences in a research report on Friday, June 14th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus price target of $14.80.

Aptose Biosciences Trading Up 3.8 %

Shares of APTO opened at $0.41 on Friday. Aptose Biosciences has a twelve month low of $0.38 and a twelve month high of $4.26. The firm’s fifty day simple moving average is $0.60 and its 200-day simple moving average is $1.11. The firm has a market capitalization of $7.33 million, a price-to-earnings ratio of -0.07 and a beta of 1.27.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.15. On average, analysts predict that Aptose Biosciences will post -2.62 earnings per share for the current fiscal year.

Institutional Trading of Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC bought a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences as of its most recent SEC filing. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.